How to choose your perfect CMO partner

What do Pharma and Biotech look for when selecting their CMO partner? The development of a new vaccine is a complex venture. Biotech and pharmaceutical companies are increasingly choosing to outsource their manufacturing efforts, as partnering with the right CMO can streamline this process. Since 2011, total global spending on contract manufacturing reached $31.9 billion according to a 2012 industry …

Novavax: Meet the decision makers

Novavax is a clinical stage vaccine developer who has been at the forefront of vaccine technology since it was founded in 1987. Based in Geithersburg, Maryland, in the US, Novavax specialises in the development and production of recombinant protein nanoparticles to produce  vaccines and virus like particles (VPLs) and recombinant protein micelles. Next Page >

Vaccine Asia Live: NIAID’s Effort on Dengue Vaccine R&D

Addressing Asia’s needs for vaccines in dengue, Dr Zou Lanling, Bacteriology Program Officer & Chief of Translational Sciences Section of National Institutes of Health USA, shared the efforts put into dengue vaccine R&D by National Institute of Allergy and Infectious Diseases(NIAID). NIAID conducts and supports research to develop vaccines, therapeutics and diagnostics to help understand, treat, and prevent infectious, immunologic, …

Vaccine Asia Live: Accelerating Vaccine Development in Asia through Public-Private Partnership(PPP)

Live at World Vaccine Congress Asia 2014, the day was opened with a panel discussion on accelerating vaccine deelopment in Asia through Public-Private Partnerships(PPP). Andrew Potter, CEO of PREVENT Canada moderated the discussion with Lanling Zou of NIAID USA, Duane Gubler of SUKW-NUS Graduate Medical School Singapore  and Stephen Cook of GSK Belgium. It was a great start to a …

Merck, Novartis, Medimmune, And Sanofi Go Head to Head

The big guns take to the stage at the World Vaccines Congress USA to talk about everything from pre-clinical all the way through to commercialisation and distribution of products. It may be a long watch but it’s well worth look if you want to know what the big players in vaccines are getting up to.

Viral hepatitis gives Asia-Pacific a wake-up call

Following a forum held last month by the Coalition to Eradicate Viral Hepatitis in Asia Pacific (CEVHAP), health experts have urged the Asia-Pacific countries to set actions against viral hepatitis as a public health priority. Recognizing the financial barriers in formulating national strategies based on the WHO framework, Jennifer Johnston, the organization’s Executive Director, stressed the need for “cross-sector partnerships”. …

Aquisition Boosts Medigene’s Immuno-oncology Portfolio

Frankfurt based Medigene last week acquired fellow Germans Trianta for the sum of €9.9 ($13.5). Trianta Immnotherapies, a Munich based  start-up, develops novel cancer vaccines and development platforms, sepcialising in personalised T cell immunotherapy. The move will see Medigene gaining 15 of the country’s top cancer vaccine researchers from the German Research Center for Environmental Health (Helmholtz Zentrum Munchen). Trianta …